Isabella Ciccone, MPH

The president at Cala Health discussed the clinical role, evidence base, and potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.

New findings presented at AAN 2025 showed that treatment with satralizumab was associated with a reduction in annualized relapse rate compared with placebo over 48 weeks in patients with MOGAD.

Data from the phase 2 Vibrance-1 trial showed that alixorexton was associated with improvements in patient-reported outcomes in adults with narcolepsy type 1 over up to 12 to 13 weeks of follow-up.

A living systematic review presented at AAN 2026 showed that GLP-1 receptor agonists demonstrated biomarker and real-world signals of neuroprotection in Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

A recently presented analysis at AAN 2026 reported comparable safety and tolerability between atogepant and erenumab, with atogepant demonstrating a greater likelihood of early response at 1 month in adults with migraine.

Real-world data of the ELEVATE-PD study, presented at AAN 2026, suggest that switching to IPX203 from other levodopa-based therapies may improve motor function in patients with Parkinson disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 17, 2026.

Findings from the phase 3 OCEANIC-STROKE study showed that the addition of asundexian, a factor XIa inhibitor, with antiplatelet therapy lowered recurrent ischemic stroke compared with placebo.

An exploratory analysis of a phase 3 trial showed that solriamfetol improved daytime wakefulness without producing consistent or clinically meaningful changes in nocturnal sleep quality measures.

In honor of International Pompe Day, held April 15, 2026, NeurologyLive reviewed recent studies on the latest research and evolving standards of care for Pompe disease.

The approved neurofilament light chain test offers a minimally invasive approach to assessing neuroaxonal damage, with potential to complement MRI in routine multiple sclerosis care.

A recent study revealed that a substantial proportion of patients with NMOSD required escalation from first-line immunosuppressants to rituximab, with baseline severe disability emerging as a key associated factor.

A recent population-based data analysis of Korean adults reported those with anxiety and certain sleep disturbances experienced longer durations of morning grogginess, known as sleep inertia.

A recent study reported that relapse prevention was the most influential factor in treatment selection, with respondents favoring profiles similar to ravulizumab over other approved options for NMOSD.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 10, 2026.

The director of neuromuscular medicine at Marcus Neuroscience Institute shared findings from an analysis presented at MDA 2026 that compared real-world infection rates associated with generalized myasthenia gravis therapies. [WATCH TIME: 8 minutes]

In recognition of National Public Health Week, held April 6-12, NeurologyLive summarizes recent literature showing that environmental exposures are associated with increased risk of neurologic disorders.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute talked about the role of research, patient empowerment, and expanding treatment options in multiple sclerosis. [WATCH TIME: 5 minutes]

A neuroimmunology fellow at the Cleveland Clinic shared her experience attending the 2026 ACTRIMS Forum, specifically focusing on the late-breaking data presented in multiple sclerosis.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute discussed the importance of early recognition of invisible symptoms in comprehensive multiple sclerosis care. [WATCH TIME: 9 minutes]

Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.

A new post hoc analysis of the CHAMPION-NMOSD trial reported similar safety and relapse prevention outcomes with ravulizumab-cwvz in patients with and without prior rituximab exposure.

Findings from a recently published study suggest peripapillary retinal nerve fiber layer thickness measured by OCT could support clinicians with early distinction between MOGAD-optic neuritis and NMOSD-optic neuritis.

Here's some of what is coming soon to NeurologyLive® this week.

A subpopulation analysis of the phase 2 ADHERE trial suggests clinical benefit and a favorable safety profile for efgartigimod PH20 in Chinese patients with chronic inflammatory demyelinating polyneuropathy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 3, 2026.

An international real-world analysis highlighted prolonged time to diagnosis and common misdiagnoses in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

A neuroimmunology fellow at the Cleveland Clinic reflected on the 2026 ACTRIMS Forum, highlighting key takeaways in multiple sclerosis research presented in the program. [WATCH TIME: 6 minutes]